Search

Your search keyword '"Goldsmith, Kelly"' showing total 404 results
Start Over Author "Goldsmith, Kelly"
404 results on '"Goldsmith, Kelly"'

1. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin

Author

Mittal, Karuna, Cooper, Garrett W., Lee, Benjamin P., Su, Yongdong, Skinner, Katie T., Shim, Jenny, Jonus, Hunter C., Kim, Won Jun, Doshi, Mihir, Almanza, Diego, Kynnap, Bryan D., Christie, Amanda L., Yang, Xiaoping, Cowley, Glenn S., Leeper, Brittaney A., Morton, Christopher L., Dwivedi, Bhakti, Lawrence, Taylor, Rupji, Manali, Keskula, Paula, Meyer, Stephanie, Clinton, Catherine M., Bhasin, Manoj, Crompton, Brian D., Tseng, Yuen-Yi, Boehm, Jesse S., Ligon, Keith L., Root, David E., Murphy, Andrew J., Weinstock, David M., Gokhale, Prafulla C., Spangle, Jennifer M., Rivera, Miguel N., Mullen, Elizabeth A., Stegmaier, Kimberly, Goldsmith, Kelly C., Hahn, William C., and Hong, Andrew L.

Published
2024
Full Text
View/download PDF

5. On the role of scarcity in marketing: Identifying research opportunities across the 5Ps

Author

Roux, Caroline, Goldsmith, Kelly, and Cannon, Christopher

Subjects
Customer relationship management -- Research, Pricing -- Research, Marketing research, Sales promotions -- Research, Product shortage, Customer relationship management, Product price, Advertising, marketing and public relations, Business
Abstract

Author(s): Caroline Roux [sup.1] , Kelly Goldsmith [sup.2] , Christopher Cannon [sup.3] Author Affiliations: (1) https://ror.org/0420zvk78, grid.410319.e, 0000 0004 1936 8630, John Molson School of Business, Concordia University, , 1450 [...]

Published
2023
Full Text
View/download PDF

7. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Author

Berko, Esther R., Witek, Gabriela M., Matkar, Smita, Petrova, Zaritza O., Wu, Megan A., Smith, Courtney M., Daniels, Alex, Kalna, Joshua, Kennedy, Annie, Gostuski, Ivan, Casey, Colleen, Krytska, Kateryna, Gerelus, Mark, Pavlick, Dean, Ghazarian, Susan, Park, Julie R., Marachelian, Araz, Maris, John M., Goldsmith, Kelly C., Radhakrishnan, Ravi, Lemmon, Mark A., and Mossé, Yaël P.

Published
2023
Full Text
View/download PDF

8. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Author

Goldsmith, Kelly C., Park, Julie R., Kayser, Kimberly, Malvar, Jemily, Chi, Yueh-Yun, Groshen, Susan G., Villablanca, Judith G., Krytska, Kateryna, Lai, Lillian M., Acharya, Patricia T., Goodarzian, Fariba, Pawel, Bruce, Shimada, Hiroyuki, Ghazarian, Susan, States, Lisa, Marshall, Lynley, Chesler, Louis, Granger, Meaghan, Desai, Ami V., Mody, Rajen, Morgenstern, Daniel A., Shusterman, Suzanne, Macy, Margaret E., Pinto, Navin, Schleiermacher, Gudrun, Vo, Kieuhoa, Thurm, Holger C., Chen, Joseph, Liyanage, Marlon, Peltz, Gerson, Matthay, Katherine K., Berko, Esther R., Maris, John M., Marachelian, Araz, and Mossé, Yael P.

Published
2023
Full Text
View/download PDF

10. An integrative theory of resource discrepancies.

Author

Cannon, Christopher, Goldsmith, Kelly, and Roux, Caroline

Subjects
*CONTROL (Psychology), *SOCIAL status, *BEHAVIORAL sciences, *CONSUMER psychology, *POWER resources
Abstract

A great deal of work in consumer psychology has been devoted to understanding how individuals manage resource discrepancies. This includes tangible resources – such as money, food, and products – as well as intangible resources – such as time, skills, and social relationships. Resource discrepancies can either be positive – as in the case of having substantial wealth – or negative – as in the case of poverty. Several constructs across the behavioral sciences have been introduced to describe how consumers perceive their various resource discrepancies including, but not limited to, power, social status, scarcity, inequality, and social class. However, little guidance is provided to understand when and why these resource‐based constructs can produce both overlapping and opposing consequences. This conceptual article provides a resolution to this issue by introducing an integrative theory that situates these constructs within the same unifying framework based on two fundamental dimensions: high (vs. low) personal control and self‐ (vs. other‐) dependence. Based on this framework, we offer eight testable propositions and develop a research agenda for academics interested in studying resource discrepancies. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

11. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G, Mosse, Yael P, Fox, Elizabeth, Kudgus, Rachel A, Reid, Joel M, McGovern, Renee, Groshen, Susan, Bagatell, Rochelle, Maris, John M, Twist, Clare J, Goldsmith, Kelly, Granger, M Meaghan, Weiss, Brian, Park, Julie R, Macy, Margaret E, Cohn, Susan L, Yanik, Greg, Wagner, Lars M, Hawkins, Randall, Courtier, Jesse, Lai, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Boucher, Najee, Czarnecki, Scarlett, Luo, Chunqiao, Tsao-Wei, Denice, Matthay, Katherine K, and Marachelian, Araz

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Cancer, Neurosciences, Pediatric, Rare Diseases, Patient Safety, Clinical Trials and Supportive Activities, Neuroblastoma, Clinical Research, 6.1 Pharmaceuticals, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Azepines, Child, Child, Preschool, Cohort Studies, Drug Monitoring, Drug Resistance, Neoplasm, Female, Humans, Infant, Irinotecan, Magnetic Resonance Imaging, Male, Neoplasm Recurrence, Local, Pyrimidines, Retreatment, Temozolomide, Tomography, X-Ray Computed, Treatment Outcome, Young Adult, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeIn phase I testing, alisertib tablets with irinotecan and temozolomide showed significant antitumor activity in patients with neuroblastoma. This study sought to confirm activity of this regimen; evaluate an alisertib oral solution; and evaluate biomarkers of clinical outcomes.Patients and methodsWe conducted a two-stage phase II trial of alisertib tablets (60 mg/m2/dose × 7 days), irinotecan (50 mg/m2/dose i.v. × 5 days), and temozolomide (100 mg/m2/dose orally × 5 days) in patients with relapsed or refractory neuroblastoma. The primary endpoint was best objective response. A separate cohort was treated with alisertib at 45 mg/m2 using oral solution instead of tablets. Exploratory analyses sought to identify predictors of toxicity, response, and progression-free survival (PFS) using pooled data from phase I, phase II, and oral solution cohorts.ResultsTwenty and 12 eligible patients were treated in the phase II and oral solution cohorts, respectively. Hematologic toxicities were the most common adverse events. In phase II, partial responses were observed in 19 evaluable patients (21%). The estimated PFS at 1 year was 34%. In the oral solution cohort, 3 patients (25%) had first cycle dose-limiting toxicity (DLT). Alisertib oral solution at 45 mg/m2 had significantly higher median C max and exposure compared with tablets at 60 mg/m2. Higher alisertib trough concentration was associated with first cycle DLT, whereas MYCN amplification was associated with inferior PFS.ConclusionsThis combination shows antitumor activity, particularly in patients with MYCN nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.

Published
2018

15. Examining the Efficacy of Time Scarcity Marketing Promotions in Online Retail.

Author

Hmurovic, Jillian, Lamberton, Cait, and Goldsmith, Kelly

Subjects
SCARCITY, SALES promotion, INTERNET marketing, MARKETING, ELECTRONIC commerce, ECONOMIC demand, TIME & economic reactions, CONSUMER behavior, CONSUMER behavior research
Abstract

Time scarcity promotions (e.g., "40% off for a limited time") are mainstays of online retail marketing. Although positive effects of time scarcity promotions on consumer interest have been evidenced in the brick-and-mortar world, should retailers expect similarly robust effects online? The present research suggests the answer may be no. First, the authors report meta-analytic and experimental results suggesting that previously identified positive effects of time scarcity promotions observed offline may not emerge in online shopping contexts. Then, consistent with the prediction that online time scarcity promotions activate more persuasion knowledge than identical control promotions, the authors detail findings suggesting that providing retailer-exogeneous justifications for online time scarcity promotions' time restriction (e.g., consumers' birthdays, seasonal changes) can increase the potential of observing positive effects on consumer interest online. Further, results suggest that the positive effects of including exogenous time justification may be more likely when less time remains until the online promotion's expiration. However, results stop short of suggesting that online time scarcity promotions will consistently yield superior outcomes compared with identical online control promotions. Therefore, the authors highlight the continued need for careful managerial use as well as further research examining the optimal translation of offline tactics to online retail. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care

Author

Summers, Ryan J., Castellino, Sharon M., Porter, Christopher C., MacDonald, Tobey J., Basu, Gargi D., Szelinger, Szabolcs, Bhasin, Manoj K., Cash, Thomas, Carter, Alexis B., Castellino, Robert Craig, Fangusaro, Jason R., Mitchell, Sarah G., Pauly, Melinda G., Pencheva, Bojana, Wechsler, Daniel S., Graham, Douglas K., and Goldsmith, Kelly C.

Published
2022
Full Text
View/download PDF

21. The effects of scarcity on consumer decision journeys

Author

Hamilton, Rebecca, Thompson, Debora, Bone, Sterling, Chaplin, Lan Nguyen, Griskevicius, Vladas, Goldsmith, Kelly, and Hill, Ronald

Subjects
Decision-making -- Research -- Social aspects -- Economic aspects, Marketing research, Product shortage, Advertising, marketing and public relations, Business
Abstract

Research in marketing often begins with two assumptions: that consumers are able to choose among desirable products, and that they have sufficient resources to buy them. However, many consumer decision journeys are constrained by a scarcity of products and/or a scarcity of resources. We review research in marketing, psychology, economics and sociology to construct an integrative framework outlining how these different types of scarcity individually and jointly influence consumers at various stages of their decision journeys. We outline avenues for future research and discuss implications for developing consumer-based marketing strategies., Author(s): Rebecca Hamilton [sup.1] , Debora Thompson [sup.1] , Sterling Bone [sup.2] , Lan Nguyen Chaplin [sup.3] , Vladas Griskevicius [sup.4] , Kelly Goldsmith [sup.5] , Ronald Hill [sup.6] , [...]

Published
2019
Full Text
View/download PDF

23. Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma

Author

Lee, Jasmine Y., primary, Jonus, Hunter C., additional, Sadanand, Arhanti, additional, Branella, Gianna M., additional, Maximov, Victor, additional, Suttapitugsakul, Suttipong, additional, Schniederjan, Matthew J., additional, Shim, Jenny, additional, Ho, Andrew, additional, Parwani, Kiran K., additional, Fedanov, Andrew, additional, Pilgrim, Adeiye A., additional, Silva, Jordan A., additional, Schnepp, Robert W., additional, Doering, Christopher B., additional, Wu, Ronghu, additional, Spencer, H. Trent, additional, and Goldsmith, Kelly C., additional

Published
2023
Full Text
View/download PDF

25. Understanding Scarcity: From Marketing to Policy, Management, and Beyond.

Author

Cannon, Christopher, Roux, Caroline, and Goldsmith, Kelly

Subjects
LIFTING & carrying (Human mechanics), HUMAN behavior, SELFISHNESS, PATIENCE, CREATIVE ability
Abstract

In a world where resources are increasingly perceived as scarce, understanding the nature of scarcity and its profound effects on human behavior has never been more critical. This monograph delves into the multifaceted dimensions of scarcity—its antecedents, manifestations, and consequences —inviting readers to explore how scarcity shapes our decisions, relationships, and societal structures. From the psychological implications of time and money scarcity to the interpersonal dynamics that arise when individuals navigate differing levels of resource availability, this work unravels the complex ways in which scarcity can influence thinking and behavior. Scarcity can drive innovation, spur creativity, and even foster resilience; yet, it also carries the weight of negative consequences like impatience and selfishness. This monograph examines the delicate balance between abundance and scarcity, challenges conventional notions, and illuminates pathways for future research. Through illuminating the rich landscape of scarcity, the authors offer not only theoretical insights but also practical implications for marketers, policymakers, and everyday individuals seeking to thrive amidst resource constraints. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors

Author

Cash, Thomas, primary, Jonus, Hunter C., additional, Tsvetkova, Maya, additional, Beumer, Jan H., additional, Sadanand, Arhanti, additional, Lee, Jasmine Y., additional, Henry, Curtis J., additional, Aguilera, Dolly, additional, Harvey, R. Donald, additional, and Goldsmith, Kelly C., additional

Published
2023
Full Text
View/download PDF

33. Supplementary Materials and Methods from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Author

Vernooij, Lindy, primary, Bate-Eya, Laurel T., primary, Alles, Lindy K., primary, Lee, Jasmine Y., primary, Koopmans, Bianca, primary, Jonus, Hunter C., primary, Schubert, Nil A., primary, Schild, Linda, primary, Lelieveld, Daphne, primary, Egan, David A., primary, Kerstjens, Mark, primary, Stam, Ronald W., primary, Koster, Jan, primary, Goldsmith, Kelly C., primary, Molenaar, Jan J., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

34. Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Author

Vernooij, Lindy, primary, Bate-Eya, Laurel T., primary, Alles, Lindy K., primary, Lee, Jasmine Y., primary, Koopmans, Bianca, primary, Jonus, Hunter C., primary, Schubert, Nil A., primary, Schild, Linda, primary, Lelieveld, Daphne, primary, Egan, David A., primary, Kerstjens, Mark, primary, Stam, Ronald W., primary, Koster, Jan, primary, Goldsmith, Kelly C., primary, Molenaar, Jan J., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Author

Vernooij, Lindy, primary, Bate-Eya, Laurel T., primary, Alles, Lindy K., primary, Lee, Jasmine Y., primary, Koopmans, Bianca, primary, Jonus, Hunter C., primary, Schubert, Nil A., primary, Schild, Linda, primary, Lelieveld, Daphne, primary, Egan, David A., primary, Kerstjens, Mark, primary, Stam, Ronald W., primary, Koster, Jan, primary, Goldsmith, Kelly C., primary, Molenaar, Jan J., primary, and Dolman, M. Emmy M., primary

Published
2023
Full Text
View/download PDF

36. Figure A1 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Author

Marachelian, Araz, primary, Villablanca, Judith G., primary, Liu, Cathy W., primary, Liu, Betty, primary, Goodarzian, Fariba, primary, Lai, Hollie A., primary, Shimada, Hiroyuki, primary, Tran, Hung C., primary, Parra, Jaime A., primary, Gallego, Richard, primary, Bedrossian, Nora, primary, Young, Sabrina, primary, Czarnecki, Scarlett, primary, Kennedy, Rebekah, primary, Weiss, Brian D., primary, Goldsmith, Kelly, primary, Granger, Meaghan, primary, Matthay, Katherine K., primary, Groshen, Susan, primary, Asgharzadeh, Shahab, primary, Sposto, Richard, primary, and Seeger, Robert C., primary

Published
2023
Full Text
View/download PDF

37. Supplemental Figure 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G., primary, Mosse, Yael P., primary, Fox, Elizabeth, primary, Kudgus, Rachel A., primary, Reid, Joel M., primary, McGovern, Renee, primary, Groshen, Susan, primary, Bagatell, Rochelle, primary, Maris, John M., primary, Twist, Clare J., primary, Goldsmith, Kelly, primary, Granger, M. Meaghan, primary, Weiss, Brian, primary, Park, Julie R., primary, Macy, Margaret E., primary, Cohn, Susan L., primary, Yanik, Greg, primary, Wagner, Lars M., primary, Hawkins, Randall, primary, Courtier, Jesse, primary, Lai, Hollie, primary, Goodarzian, Fariba, primary, Shimada, Hiroyuki, primary, Boucher, Najee, primary, Czarnecki, Scarlett, primary, Luo, Chunqiao, primary, Tsao-Wei, Denice, primary, Matthay, Katherine K., primary, and Marachelian, Araz, primary

Published
2023
Full Text
View/download PDF

38. Supplemental Table 1 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G., primary, Mosse, Yael P., primary, Fox, Elizabeth, primary, Kudgus, Rachel A., primary, Reid, Joel M., primary, McGovern, Renee, primary, Groshen, Susan, primary, Bagatell, Rochelle, primary, Maris, John M., primary, Twist, Clare J., primary, Goldsmith, Kelly, primary, Granger, M. Meaghan, primary, Weiss, Brian, primary, Park, Julie R., primary, Macy, Margaret E., primary, Cohn, Susan L., primary, Yanik, Greg, primary, Wagner, Lars M., primary, Hawkins, Randall, primary, Courtier, Jesse, primary, Lai, Hollie, primary, Goodarzian, Fariba, primary, Shimada, Hiroyuki, primary, Boucher, Najee, primary, Czarnecki, Scarlett, primary, Luo, Chunqiao, primary, Tsao-Wei, Denice, primary, Matthay, Katherine K., primary, and Marachelian, Araz, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Author

Marachelian, Araz, primary, Villablanca, Judith G., primary, Liu, Cathy W., primary, Liu, Betty, primary, Goodarzian, Fariba, primary, Lai, Hollie A., primary, Shimada, Hiroyuki, primary, Tran, Hung C., primary, Parra, Jaime A., primary, Gallego, Richard, primary, Bedrossian, Nora, primary, Young, Sabrina, primary, Czarnecki, Scarlett, primary, Kennedy, Rebekah, primary, Weiss, Brian D., primary, Goldsmith, Kelly, primary, Granger, Meaghan, primary, Matthay, Katherine K., primary, Groshen, Susan, primary, Asgharzadeh, Shahab, primary, Sposto, Richard, primary, and Seeger, Robert C., primary

Published
2023
Full Text
View/download PDF

42. Supplemental Figure 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G., primary, Mosse, Yael P., primary, Fox, Elizabeth, primary, Kudgus, Rachel A., primary, Reid, Joel M., primary, McGovern, Renee, primary, Groshen, Susan, primary, Bagatell, Rochelle, primary, Maris, John M., primary, Twist, Clare J., primary, Goldsmith, Kelly, primary, Granger, M. Meaghan, primary, Weiss, Brian, primary, Park, Julie R., primary, Macy, Margaret E., primary, Cohn, Susan L., primary, Yanik, Greg, primary, Wagner, Lars M., primary, Hawkins, Randall, primary, Courtier, Jesse, primary, Lai, Hollie, primary, Goodarzian, Fariba, primary, Shimada, Hiroyuki, primary, Boucher, Najee, primary, Czarnecki, Scarlett, primary, Luo, Chunqiao, primary, Tsao-Wei, Denice, primary, Matthay, Katherine K., primary, and Marachelian, Araz, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Table 2 from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G., primary, Mosse, Yael P., primary, Fox, Elizabeth, primary, Kudgus, Rachel A., primary, Reid, Joel M., primary, McGovern, Renee, primary, Groshen, Susan, primary, Bagatell, Rochelle, primary, Maris, John M., primary, Twist, Clare J., primary, Goldsmith, Kelly, primary, Granger, M. Meaghan, primary, Weiss, Brian, primary, Park, Julie R., primary, Macy, Margaret E., primary, Cohn, Susan L., primary, Yanik, Greg, primary, Wagner, Lars M., primary, Hawkins, Randall, primary, Courtier, Jesse, primary, Lai, Hollie, primary, Goodarzian, Fariba, primary, Shimada, Hiroyuki, primary, Boucher, Najee, primary, Czarnecki, Scarlett, primary, Luo, Chunqiao, primary, Tsao-Wei, Denice, primary, Matthay, Katherine K., primary, and Marachelian, Araz, primary

Published
2023
Full Text
View/download PDF

46. Supplemental Patients, Methods, and Tables from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Author

Marachelian, Araz, primary, Villablanca, Judith G., primary, Liu, Cathy W., primary, Liu, Betty, primary, Goodarzian, Fariba, primary, Lai, Hollie A., primary, Shimada, Hiroyuki, primary, Tran, Hung C., primary, Parra, Jaime A., primary, Gallego, Richard, primary, Bedrossian, Nora, primary, Young, Sabrina, primary, Czarnecki, Scarlett, primary, Kennedy, Rebekah, primary, Weiss, Brian D., primary, Goldsmith, Kelly, primary, Granger, Meaghan, primary, Matthay, Katherine K., primary, Groshen, Susan, primary, Asgharzadeh, Shahab, primary, Sposto, Richard, primary, and Seeger, Robert C., primary

Published
2023
Full Text
View/download PDF

47. Supplemental Figure Legends from Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Author

DuBois, Steven G., primary, Mosse, Yael P., primary, Fox, Elizabeth, primary, Kudgus, Rachel A., primary, Reid, Joel M., primary, McGovern, Renee, primary, Groshen, Susan, primary, Bagatell, Rochelle, primary, Maris, John M., primary, Twist, Clare J., primary, Goldsmith, Kelly, primary, Granger, M. Meaghan, primary, Weiss, Brian, primary, Park, Julie R., primary, Macy, Margaret E., primary, Cohn, Susan L., primary, Yanik, Greg, primary, Wagner, Lars M., primary, Hawkins, Randall, primary, Courtier, Jesse, primary, Lai, Hollie, primary, Goodarzian, Fariba, primary, Shimada, Hiroyuki, primary, Boucher, Najee, primary, Czarnecki, Scarlett, primary, Luo, Chunqiao, primary, Tsao-Wei, Denice, primary, Matthay, Katherine K., primary, and Marachelian, Araz, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results